Curosurf

Curosurf (Poractant Alfa) is a natural surfactant used for respiratory support in premature infants. This product aids in lung function and is administered via endotracheal tube.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs lack sufficient surfactant, a substance that helps keep the air sacs open. By providing external surfactant, Curosurf helps improve lung function and breathing. It is administered directly into the lungs via an endotracheal tube.

Curosurf works by replacing the natural surfactant in the lungs, which helps reduce surface tension and allows the air sacs to remain open. This can lead to improved breathing and reduced need for mechanical ventilation in premature infants. The effects are typically observed shortly after administration.

Curosurf should be administered by trained healthcare professionals in a controlled medical setting. It is important to follow proper handling and storage guidelines to maintain its effectiveness. Always consult a healthcare provider for specific precautions and contraindications.

Curosurf is generally well-tolerated, but interactions with other medications should be discussed with a healthcare provider. It is important to inform your healthcare provider about all medications and treatments being used to avoid potential interactions.